Your browser doesn't support javascript.
loading
CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022.
Ozaki, Yukio; Hara, Hironori; Onuma, Yoshinobu; Katagiri, Yuki; Amano, Tetsuya; Kobayashi, Yoshio; Muramatsu, Takashi; Ishii, Hideki; Kozuma, Ken; Tanaka, Nobuhiro; Matsuo, Hitoshi; Uemura, Shiro; Kadota, Kazushige; Hikichi, Yutaka; Tsujita, Kenichi; Ako, Junya; Nakagawa, Yoshihisa; Morino, Yoshihiro; Hamanaka, Ichiro; Shiode, Nobuo; Shite, Junya; Honye, Junko; Matsubara, Tetsuo; Kawai, Kazuya; Igarashi, Yasumi; Okamura, Atsunori; Ogawa, Takayuki; Shibata, Yoshisato; Tsuji, Takafumi; Yajima, Junji; Iwabuchi, Kaoru; Komatsu, Nobuo; Sugano, Teruyasu; Yamaki, Masaru; Yamada, Shinichiro; Hirase, Hiroaki; Miyashita, Yuusuke; Yoshimachi, Fuminobu; Kobayashi, Masakazu; Aoki, Jiro; Oda, Hirotaka; Katahira, Yoshiaki; Ueda, Kinzo; Nishino, Masami; Nakao, Koichi; Michishita, Ichiro; Ueno, Takafumi; Inohara, Taku; Kohsaka, Shun; Ismail, Tevfik F.
Afiliação
  • Ozaki Y; Department of Cardiology, Fujita Health University School of Medicine, Aichi, Japan. yukio.ozaki7@gmail.com.
  • Hara H; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.
  • Onuma Y; Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Katagiri Y; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.
  • Amano T; Department of Cardiology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
  • Kobayashi Y; Department of Cardiology, Aichi Medical University, Aichi, Japan.
  • Muramatsu T; Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
  • Ishii H; Department of Cardiology, Fujita Health University School of Medicine, Aichi, Japan.
  • Kozuma K; Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Gunma, Japan.
  • Tanaka N; Department of Cardiology, Teikyo University Hospital, Tokyo, Japan.
  • Matsuo H; Division of Cardiology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
  • Uemura S; Gifu Heart Center, Gifu, Japan.
  • Kadota K; Cardiovascular Medicine, Kawasaki Medical School, Kurashiki, Japan.
  • Hikichi Y; Kurashiki Central Hospital, Kurashiki, Japan.
  • Tsujita K; Heart Center, Saga Medical Center Koseikan, Saga, Japan.
  • Ako J; Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Nakagawa Y; Department of Cardiology, Kitasato University Hospital, Sagamihara, Japan.
  • Morino Y; Division of Cardiovascular Medicine, Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
  • Hamanaka I; Department of Cardiology, Iwate Medical University Hospital, Morioka, Japan.
  • Shiode N; Cardiovascular Intervention Center, Rakuwakai Marutamachi Hospital, Kyoto, Japan.
  • Shite J; Division of Cardiology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Honye J; Cardiology Division, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Matsubara T; Kikuna Memorial Hospital, Yokohama, Japan.
  • Kawai K; Toyohashi Heart Center, Toyohashi, Japan.
  • Igarashi Y; Chikamori Hospital, Kochi, Japan.
  • Okamura A; Sapporo-Kosei General Hospital, Sapporo, Japan.
  • Ogawa T; Sakurabashi Watanabe Hospital, Osaka, Japan.
  • Shibata Y; Division of Cardiology, The Jikei University School of Medicine, Tokyo, Japan.
  • Tsuji T; Miyazaki Medical Association Hospital, Miyazaki, Japan.
  • Yajima J; Kusatsu Heart Center, Kusatsu, Japan.
  • Iwabuchi K; The Cardiovascular Institute, Tokyo, Japan.
  • Komatsu N; Osaki Citizen Hospital, Osaki, Japan.
  • Sugano T; Ota Nishinouchi Hospital, Fukushima, Japan.
  • Yamaki M; Yokohama City University Hospital, Yokohama, Japan.
  • Yamada S; Nayoro City General Hospital, Nayoro, Japan.
  • Hirase H; Kitaharima Medical Center, Ono, Japan.
  • Miyashita Y; Takaoka Minami Heart Center, Takaoka, Japan.
  • Yoshimachi F; Nagano Red Cross Hospital, Nagano, Japan.
  • Kobayashi M; Tokai University Hachioji Hospital, Tokyo, Japan.
  • Aoki J; Department of Cardiology, Fujita Health University School of Medicine, Aichi, Japan.
  • Oda H; Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
  • Katahira Y; Niigata City General Hospital, Niigata, Japan.
  • Ueda K; Department of Cardiology, Katta General Hospital, Shiroishi, Japan.
  • Nishino M; Takase Clinic, Takasaki, Japan.
  • Nakao K; Division of Cardiology, Osaka Rosai Hospital, Osaka, Japan.
  • Michishita I; Division of Cardiology, Saiseikai Kumamoto Hospital, Cardiovascular Center, Kumamoto, Japan.
  • Ueno T; Yokohama Sakae Kyosai Hospital, Yokohama, Japan.
  • Inohara T; Fukuoka Kinen Hospital, Fukuoka, Japan.
  • Kohsaka S; Keio University School of Medicine, Tokyo, Japan.
  • Ismail TF; Keio University School of Medicine, Tokyo, Japan.
Cardiovasc Interv Ther ; 37(1): 1-34, 2022 Jan.
Article em En | MEDLINE | ID: mdl-35018605
ABSTRACT
Primary Percutaneous Coronary Intervention (PCI) has significantly contributed to reducing the mortality of patients with ST-segment elevation myocardial infarction (STEMI) even in cardiogenic shock and is now the standard of care in most of Japanese institutions. The Task Force on Primary PCI of the Japanese Association of Cardiovascular Interventional and Therapeutics (CVIT) society proposed an expert consensus document for the management of acute myocardial infarction (AMI) focusing on procedural aspects of primary PCI in 2018. Updated guidelines for the management of AMI were published by the European Society of Cardiology (ESC) in 2017 and 2020. Major changes in the guidelines for STEMI patients included (1) radial access and drug-eluting stents (DES) over bare-metal stents (BMS) were recommended as a Class I indication, (2) complete revascularization before hospital discharge (either immediate or staged) is now considered as Class IIa recommendation. In 2020, updated guidelines for Non-ST-Elevation Myocardial Infarction (NSTEMI) patients, the followings were changed (1) an early invasive strategy within 24 h is recommended in patients with NSTEMI as a Class I indication, (2) complete revascularization in NSTEMI patients without cardiogenic shock is considered as Class IIa recommendation, and (3) in patients with atrial fibrillation following a short period of triple antithrombotic therapy, dual antithrombotic therapy (e.g., DOAC and single oral antiplatelet agent preferably clopidogrel) is recommended, with discontinuation of the antiplatelet agent after 6 to 12 months. Furthermore, an aspirin-free strategy after PCI has been investigated in several trials those have started to show the safety and efficacy. The Task Force on Primary PCI of the CVIT group has now proposed the updated expert consensus document for the management of AMI focusing on procedural aspects of primary PCI in 2022 version.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Stents Farmacológicos / Intervenção Coronária Percutânea / Infarto do Miocárdio com Supradesnível do Segmento ST / Infarto do Miocárdio Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Cardiovasc Interv Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Stents Farmacológicos / Intervenção Coronária Percutânea / Infarto do Miocárdio com Supradesnível do Segmento ST / Infarto do Miocárdio Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Cardiovasc Interv Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão